CAS Number35607-66-0
SynonymsEINECS 252-641-2; CEFOXITIN ACID; MFCD00072014; Cefoxitin; Rephoxitin; CFX; 3-Carbamoyloxymethyl-7a-methoxy-7-[2-(2-thienyl)acetamido]-3-cephem-4-carboxylic Acid; Mefoxin; cephoxitin
Molecular FormulaC16H17O7N3S2
Molecular Weight427.46
Purity98%
Density1.6±0.1 g/cm3
Boiling Point843.4±65.0 °C at 760 mmHg
Melting Point149 - 150ºC
AppearanceWhite to off-white crystalline powder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 35607-66-0 |
| Catalog No. | 2A-9009656 |
| Chinese Name | 头孢西丁 |
| Synonyms | EINECS 252-641-2; CEFOXITIN ACID; MFCD00072014; Cefoxitin; Rephoxitin; CFX; 3-Carbamoyloxymethyl-7a-methoxy-7-[2-(2-thienyl)acetamido]-3-cephem-4-carboxylic Acid; Mefoxin; cephoxitin |
| Molecular Formula | C16H17O7N3S2 |
| Molecular Weight | 427.46 |
| Purity | 98 |
| Density | 1.6±0.1 g/cm3 |
| Boiling Point | 843.4±65.0 °C at 760 mmHg |
| Melting Point | 149 - 150ºC |
| Appearance | White to off-white crystalline powder |
| Water Solubility | Water solubility: Practically insoluble; soluble i |
| Storage Condition | Warehouse low temperature ventilation and drying |
| Packaging | III |
| Application | Cefoxitin is a broad-spectrum, second-generation cephalosporin with antimicrobial activity. Cefoxitin is effective against a variety of infections caused by Gram-positive/Gram-negative aerobic and ana |
| HTC | 3003201300 |
| MDL Number | MFCD00072014 |
| SMILES | COC1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC21 |
| InChI | InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1 |
| InChI Key | WZOZEZRFJCJXNZ-ZBFHGGJFSA-N |
| MSDS | msds/9656_1_35607_66_0.pdf |
| Use of | Cefoxitin is a broad-spectrum, second-generation cephalosporin with antibacterial activity. Cefoxitin is effective against a wide variety of infections caused by gram-positive or gram-negative aerobes as well as by anaerobic bacteria[1][2]. Properties Name cefoxitin Synonym More Synonyms Cefoxitin Biological Activity Description Cefoxitin is a broad-spectrum, second-generation cephalosporin with antibacterial activity. Cefoxitin is effective against a wide variety of infections caused by gram-positive or gram-negative aerobes as well as by anaerobic bacteria[1][2]. Related Catalog Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial In Vitro Cefoxitin has good activity against gram-positive bacteria. The MICs for several gram-positive pathogens are in the range of 1-6 μg/mL[1]. Cefoxitin has shown high efficacy killing B. burgdorferi at concentration of 1.25 µM/mL[3]. References [1]. E O Stapley, et al. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. Jan-Feb 1979;1(1):73-89. [2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37. [3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915-2921. Chemical & Physical Properties Molecular Formula C16H17N3O7S2 Exact Mass 427.050781 PSA 201.80000 Index of Refraction 1.693 InChIKey WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Toxicological Information CHEMICAL IDENTIFICATION RTECS NUMBER : CHEMICAL NAME : 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7- methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)- CAS REGISTRY NUMBER : 35607-66-0 LAST UPDATED : DATA ITEMS CITED : MOLECULAR FORMULA : C16-H17-N3-O7-S2 MOLECULAR WEIGHT : WISWESSER LINE NOTATION : T46 ANV ES GUTJ CO1 G1OVZ HVQ CMV1- BT5SJ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - woman DOSE/DURATION : TOXIC EFFECTS : Blood - leukopenia REFERENCE : AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 92,874,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Gastrointestinal - hypermotility, diarrhea REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl1),150,1978 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Skin and Appendages - dermatitis, other (after systemic exposure) Skin and Appendages - hair REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl 1),150,1978 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl 1),150,1978 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Gastrointestinal - hypermotility, diarrhea REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl1),150,1978 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression Skin and Appendages - hair REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl 1),150,1978 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl 1),150,1978 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl1),150,1978 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Gastrointestinal - other changes Blood - changes in leukocyte (WBC) count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl 1),150,1978 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Kidney, Ureter, Bladder - urine volume increased Nutritional and Gross Metabolic - changes in sodium Nutritional and Gross Metabolic - changes in chlorine REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl 1),150,1978 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Immunological Including Allergic - decrease in humoral immune response REFERENCE : TOLED5 Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977- Volume(issue)/page/year: 13,129,1982 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3193 No. of Facilities: 222 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 14543 (estimated) No. of Female Employees: 12733 (estimated) Safety Information RIDADR UN 3077 Packaging Group III HS Code 3003201300 Synthetic Route (6R)-3-carbamoy... CAS#:35607-68-2 CAS#:35607-66-0 Literature: Shiozaki, Masao; Ishida, Noboru; Iino, Kimio; Hiraoka, Tetsuo Tetrahedron, 1980 , vol. 36, p. 2735 - 2740 cephamycin C CAS#:32178-84-0 CAS#:35607-66-0 Literature: Tetrahedron, , vol. 36, p. 2735 - 2740 CAS#:35664-28-9 CAS#:35607-66-0 Literature: Tetrahedron, , vol. 36, p. 2735 - 2740 Precursor & DownStream Precursor 6 CAS#:35607-68-2 (6R)-3-carbamoy... CAS#:32178-84-0 cephamycin C CAS#:66893-40-1 diphenylmethyl ... CAS#:68318-53-6 2-(((6R,7S)-2-(... DownStream 0 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Cefonicid sodium | 61270-78-8 | 2A-9009647 |
| Cefoperazone acid | 62893-19-0 | 2A-9009648 |
| Cefoperazone sodium | 62893-20-3 | 2A-9009649 |
| Cefotetan; Cefotetan sodium | 69712-56-7 | 2A-9009653 |
| Cefotiam | 66309-69-1 | 2A-9009655 |
| Cefoxitin sodium | 33564-30-6 | 2A-9009657 |
| Cefozopran | 113359-04-9 | 2A-9009658 |
| Cefpimizole | 84880-03-5 | 2A-9009659 |
| Cefpiramide | 70797-11-4 | 2A-9009660 |
| Cefpirome | 84957-29-9 | 2A-9009662 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS